Epiminder Says US Clinical Study Evaluating Epilepsy Monitoring Platform Enrolls 75th Patient
MT Newswires Live
4 hours ago
Epiminder (ASX:EPI) said its Detect US clinical study enrolled its 75th patient, according to a Thursday Australian bourse filing.
The recruitment is in line with expectations and the firm remains on track to enroll 210 patients by end of the first half of 2027, the firm's Chief Executive Rohan Hoare said.
The study is evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy following an inconclusive prolonged electroencephalographic monitoring assessment.
The medical device company's shares rose nearly 2% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.